DNA of bone tumor cells

"DNA in bone tumor cells" encompasses the genomic and epigenetic landscape of malignant bone tumor populations. Analysis of tumor DNA, including mutations, copy number changes, and methylation profiles, is foundational for molecular classification of bone tumors (such as distinguishing osteosarcoma, Ewing sarcoma, and other sarcoma subtypes)[1][5][3][7]. Tumor DNA is not itself a molecular therapeutic target, but profiling DNA enables identification of actionable mutations (e.g., TP53, BRCA1/2, RB1) and informs targeted treatment strategies such as PARP inhibition in homologous recombination-deficient cancers[4][6][7]. DNA methylation signatures provide robust molecular classifiers to supplement histopathological diagnosis[3][5]. Genomic instability and ongoing DNA alteration drive tumor progression, therapeutic resistance, and complications in bone tumor management[1][10]. Importantly, while drugs may directly damage DNA or inhibit DNA repair pathways, clinical targeting is focused on specific genes or DNA-associated processes rather than tumor DNA as a generic entity[2][4][6].

Other names

Tumor DNABone tumor genomic alterationsBone tumor cell DNADNA methylation profile in bone tumor cells

DNA damage induction (e.g., alkylating agents disrupt DNA) and DNA repair inhibition (e.g., PARP inhibitors kill tumor cells with homologous recombination deficiency) indirectly affect this target.